Posts tagged American Society of Clinical Oncology
Chi-Med initiates fruquintinib clinical trial in U.S.

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.

Read More